Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KET01
- Development stage
- Unknown
- Lead developer
- Ketabon
- Modality
- Drug Delivery Systems, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
KET01 is a proprietary, oral prolonged-release formulation of racemic ketamine developed as an adjunctive treatment for major depressive disorder (MDD), with a primary focus on treatment-resistant depression (TRD). Unlike traditional intravenous or intranasal ketamine therapies, KET01 is designed for at-home use and aims to provide rapid antidepressant effects while minimizing the dissociative and cardiovascular side effects commonly associated with other ketamine-based treatments. Clinical trials have demonstrated that KET01 can induce early improvements in depressive symptoms, with minimal incidences of dissociation or cardiovascular adverse events. The drug is currently progressing into pivotal Phase 3 clinical trials following promising results from Phase 2 studies[2][4][6][7][9].
- Brand names
- Ketabon
- Other names
- ketamine prolonged-release
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on KET01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KET01.